Skip to content
TickerMagic

Ajanta Pharma Limited

AJANTPHARMNSEHealthcare
₹3,270.3
-3.50 (-0.11%) · EOD 2026-11-20

Our verdict

Hold

Quality (88/100) does the heavy lifting; valuation (34/100) is the drag.

Fair valueHealth A
Quality 88Momentum 42Value 34Trend 72The Spark ↓

Our fair value

Overvalued by 14%
₹2,801.77down 14.33%
Price ₹3,270Range ₹1,635 – ₹3,174

Buy-below (20% margin of safety): ₹2,241.42

The bottom line

Ajanta Pharma Limited earns a Hold from TickerMagic, with a blended score of 59/100. At ₹3,270.3 it trades above our blended DCF and relative-multiples fair value of ₹2,801.77, about 14% downside to that estimate — we read it as overvalued by 14%. On 38.5x trailing earnings it sits roughly in line with the Healthcare median of about 37.4x. The price is about 12% below its 52-week high of ₹3,718.2 and 33% above the low of ₹2,463.14. Financial health scores 100/100, in the safe band on the Altman Z-score, with a Piotroski F-score of 4/9. The average analyst target of ₹3,303.29 implies about 1% upside across 14 analysts. It clears 9 of 13 investability checks, with durability 88, valuation 42 and momentum 42 on our 0–100 scales.

Analysis by Ankit Sharma · TickerMagic's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.

Intrinsic value
Our fair value
₹2,801.77down 14.33%
Overvalued by 14%
Price ₹3,270.3Range ₹1,635.15–₹3,174.26
DCF + relative blendhigh confidence

With a 20% margin of safety, our buy-below price is ₹2,241.42.

Analyst views

14 analysts12 buy · 0 hold · 1 sell
12-month consensus target₹3,303.29up 1.01%

1-year price

EOD · 2026-11-20
1D
down 0.11%
1W
down 1.62%
1M
down 0.87%
3M
down 11.77%
6M
up 1.60%
1Y
—

52-week range

-12.05% from the 52-week high.

Trend check
Below 50-DMA₹3,427Above 200-DMA₹3,186

Price above both moving averages reads as an intact uptrend; below both, the trend is against you.

Verdict pillars

Hold59
A
Financial health 100/100
Altman Z 17.33 · Safe zone

Piotroski F-score 4/9 — quality of earnings & balance sheet.

Our scores

Durability88
Valuation42
Momentum42

Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.

Investability checklist

Passed 9 of 13 checks
Each check screens one fundamentals, valuation or trend signal.
  • Pass: ROE above 15%: 25.4%
  • Pass: Low debt (D/E < 0.5): 0.06x
  • Pass: Positive free cash flow
  • Pass: Revenue growth > 10%: 22%
  • Pass: Earnings growing: 19%
  • Pass: Net margin ≥ 10%: 19.4%
  • Pass: Current ratio > 1.5: 2.64
  • Fail: Below our fair value
  • Fail: Margin of safety ≥ 20%
  • Pass: Above 200-day average
  • Fail: Above 50-day average
  • No data: Positive 1-year return
  • Pass: Altman Z in safe zone: Z 17.33
  • Fail: Piotroski ≥ 7: 4/9

Quarterly results

Revenue · 1Q2026
₹1,422 Cr
Net profit
₹267 Cr
Margin
19%
2Q2025
3Q2025
4Q2025
1Q2026
Revenue Net profitLatest revenue QoQ +3%

Annual financials

Revenue · 2026
₹5,453 Cr
Net profit
₹1,056 Cr
Margin
19%
2023
2024
2025
2026
Revenue Net profitLatest revenue YoY +17%

Shareholding

  • Promoter63.4%
  • Institutions21.7%
  • Public & other14.9%

Promoter holding via insider stake; institutional via reported holdings.

Key fundamentals

Market cap
₹40,675 Cr
P/E ratio
38.5
P/B ratio
8.98
EPS (TTM)
₹84.47
ROE
25.4%
Debt / Equity
0.06x
Profit margin
19.4%
Free cash flow
₹1 Cr
52-week high
₹3,718.2
-12.05% from high
52-week low
₹2,463.14
Dividend yield
1.8%
Beta
0.20
SWOT snapshot

Bull case vs bear case

Bull case

Strengths

  • Strong return on equity (25.4%).
  • Lightly leveraged balance sheet.
  • Healthy profit margin (19.4%).
  • Financially solid — Altman Z 17.33.

Opportunities

  • Earnings growing (19% YoY).
  • Revenue growing (22% YoY).

About Ajanta Pharma Limited

Ajanta Pharma and its subsidiaries develop, manufacture, and market specialty pharmaceutical formulations across multiple dosage forms including tablets, capsules, injectables, inhalers, ointments, creams, and liquids. The company produces chronic and acute therapies as branded generic products, serving therapeutic areas in cardiology, dermatology, ophthalmology, and pain management.

Ajanta Pharma Limited — frequently asked questions

Is Ajanta Pharma Limited a buy, hold or sell?

TickerMagic currently rates Ajanta Pharma Limited (AJANTPHARM) a Hold, based on a blended score of 59/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.

What is Ajanta Pharma Limited's fair value?

Our blended DCF and relative-valuation model estimates Ajanta Pharma Limited's fair value at about ₹2,801.77, versus a current price of ₹3,270.3 — roughly 14% downside. On that basis the stock looks overvalued by 14%.

Is Ajanta Pharma Limited financially healthy?

Ajanta Pharma Limited scores 100/100 on our financial-health model, placing it in the safe band on the Altman Z-score, with a Piotroski F-score of 4/9.

How has Ajanta Pharma Limited's share price performed?

Ajanta Pharma Limited is down 12% over three months, and last traded at ₹3,270.3. Past performance doesn't predict future returns.

Our verdict, fair value, financial-health and checklist are TickerMagic's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.